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Supplemental content
IMPORTANCE Psoriasis is a chronic, inflammatory skin disease and has significant associated

morbidity and effect on quality of life. It is important to determine whether dietary
interventions help reduce disease severity in patients with psoriatic diseases.
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OBJECTIVE To make evidence-based dietary recommendations for adults with psoriasis
and/or psoriatic arthritis from the Medical Board of the National Psoriasis Foundation.
EVIDENCE REVIEW We used literature from prior systematic reviews as well as additional
primary literature from the MEDLINE database from January 1, 2014, to August 31, 2017, that
evaluated the impact of diet on psoriasis. We included observational and interventional
studies of patients with psoriasis or psoriatic arthritis. The quality of included studies was
assessed using the Newcastle-Ottawa scale for observational studies and the Cochrane Risk
of Bias Tool for interventional studies. We made evidence-based dietary recommendations,
which were voted on by the National Psoriasis Foundation Medical Board.
FINDINGS We identified 55 studies meeting the inclusion criteria for this review. These studies
represent 77 557 unique participants of which 4534 have psoriasis. Based on the literature,
we strongly recommend dietary weight reduction with a hypocaloric diet in overweight and
obese patients with psoriasis. We weakly recommend a gluten-free diet only in patients who
test positive for serologic markers of gluten sensitivity. Based on low-quality data, select
foods, nutrients, and dietary patterns may affect psoriasis. For patients with psoriatic
arthritis, we weakly recommend vitamin D supplementation and dietary weight reduction
with a hypocaloric diet in overweight and obese patients. Dietary interventions should always
be used in conjunction with standard medical therapies for psoriasis and psoriatic arthritis.
CONCLUSIONS AND RELEVANCE Adults with psoriasis and/or psoriatic arthritis can supplement
their standard medical therapies with dietary interventions to reduce disease severity. These
dietary recommendations from the National Psoriasis Foundation Medical Board will help
guide clinicians regarding the utility of dietary interventions in adults with psoriatic diseases.
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P

soriasis is a chronic, inflammatory skin disease that affects
3.2% of US adults1 and has a substantial effect on quality of
life.2,3 In addition to skin manifestations, psoriasis is associated with many comorbidities including psoriatic arthritis, cardiometabolic disease, gastrointestinal disease, and mood disorders.2
Various medical therapies exist for psoriatic diseases including topical agents, phototherapy, oral medications, and biologics.3 Prescription drugs and medical phototherapy have undergone rigorous efficacy and safety evaluation via clinical trials and long-term registries.
Regardless of patients’ perspectives on established medical therapies, nearly all patients seek to understand how diet affects their psoriatic disease.4
Specifically, most patients deem dietary interventions to be relevant to their overall psoriatic disease management; however, diet
is rarely discussed during clinical visits.4,5 Furthermore, studies show
that patients with psoriasis are highly motivated to carry out dietary changes because these interventions are perceived to be natural, safe, and patient initiated.5,6 However, most patients and clinicians lack knowledge on how well dietary interventions work because
few articles exist that summarize literature on psoriasis and diet.4,7-10
Overall, there is a critical lack of evidence synthesis on the
relationship between psoriatic diseases and diet. This literature
gap speaks to the need for evidence-based dietary recommendations that are accessible to clinicians and patients. In this article,
we present evidence synthesis from a systematic review that
answers key questions on the role of dietary interventions in psoriatic diseases. Based on this systematic review, we present
evidence-based recommendations from the National Psoriasis
Foundation (NPF) Medical Board on the role of dietary interventions in psoriatic diseases.

Methods
Systematic Review
To explore the current evidence relating to diet and psoriasis, we leveraged prior reviews that used Cochrane Central Register of Controlled Trials in the Cochrane Library, MEDLINE, and EMBASE4,7-10
and performed additional systematic review synthesizing primary
literature from 2014 through 2017 from MEDLINE. For evaluation
of additional primary studies from January 1, 2014, to August 31, 2017,
we used the following search criteria in MEDLINE: (“Psoriasis” [medical subject heading {MeSH}] AND “Diet, Food, and Nutrition” [MeSH])
OR “Psoriasis/diet therapy” [MeSH]. Through reading of primary literature, we identified additional studies not identified through the
MEDLINE search (Figure).5,11,12
This review included observational and interventional studies
(controlled and uncontrolled). The studies must have met the following inclusion criteria: study participants must have psoriasis
and/or psoriatic arthritis; studies must use a dietary or nutritional
intervention or examine food intake and/or dietary patterns;
outcomes must include the development of psoriasis, psoriatic disease severity, or patient-reported effects of diet on disease severity. We excluded case reports, case series, review articles, nonEnglish language studies, and studies exclusively evaluating alcohol
as a dietary component.
Two authors (A.R.F. and A.W.A.) read reference abstracts to
determine eligibility based on inclusion and exclusion criteria.
jamadermatology.com
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Key Points
Question What dietary interventions help adult patients with
psoriasis and/or psoriatic arthritis reduce their disease severity?
Findings In this systematic review of 55 studies and 4534 patients
with psoriasis, we identify the strongest evidence for dietary
weight reduction with a hypocaloric diet in overweight and obese
patients with psoriasis. The utility of gluten-free diet and
supplementation with vitamin D varies by subpopulations of
adults with psoriatic diseases, and evidence is low for the utility of
specific foods, nutrients, and dietary patterns in reducing psoriatic
disease activity.
Meaning Adults with psoriasis and/or psoriatic arthritis can
supplement their medical therapies with dietary interventions to
reduce disease severity.

Selected studies underwent full-text review. Two of us (A.R.F. and
A.W.A.) independently extracted the data. We performed quality
assessment using the Newcastle-Ottawa scale for observational
studies and the Cochrane Risk of Bias Tool for interventional studies. The quality of uncontrolled interventional studies was not
assessed.

Recommendation Development
Recommendations were developed using established guidance by
Robinson et al13 to determine the strength of recommendations and
the level of supporting evidence. The findings from the systematic
review and the proposed recommendations were reviewed and approved by majority vote by the NPF Medical Board.
Briefly, level of evidence determines the strength of
recommendation13:
• Level of evidence “A” refers to high-quality, patient-oriented evidence, which leads to a “strong recommendation” (strength of
recommendation 1).
• Level of evidence “B” refers to limited-quality, patient-oriented evidence, which leads to a “weak recommendation” (strength of recommendation 2A).
• Level of evidence “C” refers to low-quality evidence, which leads
to a “weak recommendation” (strength of recommendation 2B).

Results of the Systematic Review
and NPF Recommendations
Fifty-five studies meet the inclusion criteria for this systematic review (Figure). These studies represent a total of 77 557 unique participants of which 4534 have psoriasis. Although a small number of
pediatric patients are included in some studies, the data are insufficient to make recommendations for pediatric psoriasis. Study characteristics and outcome data are summarized in Table 15,27,29,51,60,61
and Table 2.11,12,14-16,19-28,30,33-41,44-50,52,54-58,62,63,66-75 Quality assessment results for observational studies are included in Table 1;
results for interventional studies are reported in the eTable in the
Supplement. Dietary recommendations are summarized in
Table 3.13-17,19-23,45,60-63
(Reprinted) JAMA Dermatology August 2018 Volume 154, Number 8
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Figure. Diet and Psoriasis Literature Search and Screening Results
48 Records identified through PubMed search
42 Additional records identified from prior systematic reviews
3 Additional records identified from plain language search

93 Records screened

30 Records excluded after reviewing
abstracts

63 Full-text articles assessed for eligibility

8 Full-text articles excluded
6 Outcome was not disease severity
1 Intervention was not nutritional
1 Review article

55 Studies included in the systematic review

Question 1: Are Gluten-Free Diets Helpful in Psoriasis?
Psoriasis is associated with an increased risk of several autoimmune diseases; this includes a greater than 2-fold increased frequency of celiac disease.7 Celiac disease is characterized by a small
intestinal inflammatory response to dietary gluten. Serum antibodies indicating gluten sensitivity (IgG tissue transglutaminase, IgA endomysial antibody) are used to screen for celiac disease. Definitive
diagnosis of celiac disease is made by demonstration of characteristic findings on duodenal biopsy. Of note, controversy exists regarding the existence of gluten sensitivity (characterized by positive serologic markers) in the absence of celiac disease.
Patients with psoriasis have an increased risk of positivity for
serologic markers of gluten sensitivity, and higher antibody levels
are associated with greater psoriasis severity.7 Some patients with
psoriasis have markers of gluten sensitivity with normal
duodenal biopsy results.7,14 Therefore, some patients with psoriasis seem to have gluten sensitivity in the absence of celiac disease.
Based on the available literature, a gluten-free diet may be helpful in select patients with psoriasis.14-16 In patients with confirmed
celiac disease, a gluten-free diet not only ameliorates gastrointestinal symptoms but also reduces psoriasis severity.16 In patients who
test positive for serologic markers of gluten sensitivity, a gluten-free
diet leads to significant improvements in both clinical psoriasis severity and skin biopsy findings after 3 months.14,15 Histologically, a
decrease in the number of inflammatory and proliferating cells is seen
in psoriatic plaques.15 A majority of these patients experience worsening of disease after resuming a regular diet.14 Additionally, among
patients who test positive for serologic markers of gluten sensitivity, a gluten-free diet seems to be beneficial regardless of duodenal
biopsy results.14-16 In contrast, studies show that a gluten-free diet
is not helpful in patients with psoriasis who test negative for serologic markers of gluten sensitivity.14,15

Recommendation 1: Gluten-Free Diet in Psoriasis
• In adults with psoriasis with confirmed celiac disease, we strongly
recommend a gluten-free diet.16,17
936

• This strong recommendation (strength 1) is based on level A
evidence.
• Only in adults with psoriasis who test positive for serologic
markers of gluten sensitivity, we recommend a 3-month trial of a
gluten-free diet as an adjunctive intervention to standard medical therapies for psoriasis.
• We do not recommend universal screening for serologic markers
of gluten sensitivity among adults with psoriatic diseases
because of a high rate of false-positive results. 18 Based on
recommendations from the American College of Gastroenterology, patients who are candidates for screening include those
with a first-degree relative with celiac disease or those with
active gastrointestinal symptoms.17
• This weak recommendation (strength 2A) is based on level B
evidence; limitations include a lack of randomization, small
control groups, no reporting of between-group comparisons,
and study-related bias.14-16

Question 2: What Is the Association of Dietary Weight
Reduction With Psoriasis?
There is a well-established link between obesity and psoriasis.2,9 Excess body weight is associated with increased psoriasis incidence,
higher psoriasis severity, and reduced response to psoriasis
treatments.2,4,9 These associations may be mediated by the proinflammatory effects of body fat.4
Dietary weight reduction refers to weight loss as a result of dietary interventions and not from exercise or surgery. From the literature on dietary weight reduction, we learn that weight reduction with
a hypocaloric diet—one that delivers less energy per day than an individual’s expenditure—can be helpful in patients with psoriasis who
are overweight or obese, defined as a body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) of
25 or more. In these patients, a hypocaloric diet leads to significant
improvements in psoriasis severity,19-22 dermatology quality of life,21,23
and weight loss,19-23 compared with patients consuming a regular diet.
The duration of beneficial dietary interventions ranges from 16 weeks
to 6 months, and improvements in skin disease severity and
dermatology quality of life can be maintained after 1 year.24 The energy content of hypocaloric diets ranges from 800 to 1400 kcal per
day.19-23 Dietaryweightreductionisbeneficialinconjunctionwithstandard psoriasis treatments including biologic therapy, 19,22,23
cyclosporine,20-22 methotrexate,21-23 acitretin,22 phototherapy,22 and
various topical therapies.22 Further support comes from 2 recent systematic reviews, 1 with a meta-analysis, that demonstrate significant
benefit of weight loss with a hypocaloric diet in overweight and obese
patients with psoriasis.4,9 Uncontrolled data also support a hypocaloric diet in these patients for improvement in skin disease severity,
dermatology quality of life, and weight loss.24-26
In 1 randomized clinical trial (RCT), after maintaining remission for
12 weeks during methotrexate therapy, patients discontinued methotrexate and were randomized to hypocaloric vs regular diet. The hypocaloric diet group had lower psoriasis severity scores compared with
the regular diet group, but this was not statistically significant. Thus,
diet alone may not be sufficient to maintain psoriasis remission.27
Limited data exist regarding other diets in patients with psoriasis. Ornish and South Beach diets helped patients with psoriasis
achieve weight loss in an RCT, but their long-term benefit on psoriasis severity is uncertain.28
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Table 1. Observational Studies on Dietary Patterns and Dietary Supplements in Psoriasis
Source; Country

Design/
No. of Participants

Participant
Characteristics

Measures

Outcomes

Qualitya

Vitamin D Supplementation
Merola et al,51
2014; United
States

Cohort/
70 437 (502
psoriasis), 973 057
person-years of
follow-up

No psoriasis at
baseline (1994),
female, age
47-74 y, enrolled
in Nurses’ Health
Study

Food frequency
questionnaire in
1994, 1998, 2002,
2006 to assess
vitamin D intake

No significant association between vitamin D intake (dietary,
supplementary, total) and incident psoriasis. RR of psoriasis in
patients taking varying levels of vitamin D vs those taking
300-399 IU/d of vitamin D: 0.60 (95% CI, 0.24-1.50) for
>1000 IU/d, 1.23 (95% CI, 0.80-1.87) for 800-999 IU/d,
1.05 (95% CI, 0.81-1.36) for 400-799 IU/d, 0.98
(95% CI, 0.71-1.35) for <200 IU/d (P > .99.

5

Case-control/
138 Psoriasis,
138 controls

Patients with
psoriasis:
biopsyconfirmed plaque
psoriasis, age
20-91 y.
Controls: no
dermatologic
discomfort,
age >20 y.

Questionnaire to
assess supplement
use over 30 d, PASI,
DLQI

Patients with psoriasis vs controls: Compared with controls,
higher proportion of patients with psoriasis used supplements
(72.5% vs 25.4%; P = .01). Among patients with psoriasis: no
significant difference in psoriasis severity or dermatology
quality of life between patients with psoriasis using and not
using supplements or between those using different
supplements. Among patients with psoriasis, most common
supplements were multivitamins (26.8%), folic acid (21.7%),
herbs (12.3%), ω-3/fish oil (10.1%), vitamin E (1.4%).

4

Barrea et al,60
2015; Italy

Case-control/
62 Psoriasis,
62 controls

Patients with
psoriasis:
mild-to-severe
plaque psoriasis,
duration >6 mo,
adults,
treatment-naive.
Controls: healthy
subjects matched
for sex, age, BMI.

PREDIMED
questionnaire
measuring adherence
to Mediterranean
diet, PASI

8
Patients with psoriasis vs controls: Compared with controls,
patients with psoriasis had lower adherence to the
Mediterranean diet (P < .001). Compared with controls, a
smaller proportion of patients with psoriasis consumed EVOO as
main lipid, fruit ≥3 servings/d, fish or seafood ≥3/wk, tree nuts
≥3/wk. Among patients with psoriasis: Lower psoriasis severity
was associated with consuming EVOO as main lipid, vegetables
≥2 servings/d, fruits ≥3 servings/d, legumes ≥3/wk, fish or
seafood ≥3/wk, tree nuts ≥3/wk, sofrito sauce ≥2/wk
(P < .009). Adherence to Mediterranean diet and consuming
EVOO were predictors of lower psoriasis severity (P = .007 and
P < .001, respectively).

Barrea et al,61
2015; Italy

Case-control/
41 Psoriasis,
41 controls

7-d food record to
Patients with
psoriasis: plaque measure energy and
nutrient intake, PASI
psoriasis, male,
adults, white,
treatment-naive.
Controls: healthy
subjects matched
for age, BMI.

Afifi et al,5
2017;
United States

Case-control/
1206 Psoriasis,
2847 controls

Patients with
psoriasis:
members of NPF
listserv;
self-reported
severity, 20.9%
mild, 42.2%
moderate, 36.9%
severe; 43.9%
with psoriatic
arthritis; mean
age, 50.4 y;
87.2% white;
79% urban.
Controls:
NHANES
2009-2010 data
set matched for
sex, age.

NHANES 2009-2010
dietary screening
questionnaire to
assess nutrient
intake; questionnaire
to assess
patient-reported skin
responses to dietary
changes and patients’
attitudes regarding
diet and psoriasis

4
Patients with psoriasis vs controls: Compared with controls,
patients with psoriasis had lower daily intake of sugar, whole
grain fiber, dairy products, calcium (P < .001); higher daily
intake of fruits/vegetables/legumes (P = .007). Among patients
with psoriasis (psoriasis patient perceptions): Triggers that
worsen psoriasis: sugar (13.8%), alcohol (13.6%), tomato
(7.4%), gluten (7.2%), dairy (6%). Items that may improve
psoriasis: supplements (unspecified) (35.1%), vegetables
(26.5%), fruits (21.8%), water (11.2%), fish (9.2%). Dietary
reductions associated with patient-reported psoriasis
improvement: alcohol (53.8%), gluten (53.4%), nightshades
(52.1%), junk foods (50.4%), white flour products (49.9%).
Dietary additions associated with patient-reported psoriasis
improvement: fish oil/ω-3 (44.6%), vegetables (42.5%), oral
vitamin D supplementation (41%), probiotics (40.6%), organic
foods (38.4%), fruits (34.6%). Forty percent of patients with
psoriasis had tried special diet for psoriasis; patients reported
most psoriasis improvement with Pagano, vegan, Paleolithic
diet.

Del Giglio
et al,27 2012;
Italy

Cross-sectional/
200

Plaque psoriasis,
PASI >10 or PASI
>5 but
uncontrolled by
topical therapy,
mean (SD) age,
53 (14) y

Questionnaire to
assess opinions on
possible dietary
approach to psoriasis,
BMI

Psoriasis patient perceptions: body weight can influence
psoriasis severity (19%), foods can improve psoriasis (38%)
(fruits and vegetables 60%, fish 10%), foods can worsen
psoriasis (46%) (sausages 20%, dairy products 8%, tomatoes
8%, spicy food and chocolate 7%, fried food 5%), diet regimen
can improve psoriasis (62%). Compared with normal weight
patients with psoriasis, significantly more overweight/obese
patients thought body weight can influence psoriasis severity
(P < .003) and diet regimen can improve psoriasis (P < .04).

Supplement Use
Yousefzadeh
et al,29 2017;
Iran

Dietary Patterns

Abbreviations: BMI, body mass index; DLQI, Dermatology Life Quality Index;
EVOO, extra virgin olive oil; MUFA, monounsaturated fatty acid; NHANES,
National Health and Nutrition Examination Survey; NPF, National Psoriasis
Foundation; PASI, Psoriasis Area and Severity Index; PREDIMED, Prevención
con Dieta Mediterránea; PUFA, polyunsaturated fatty acid; RR, relative risk.

jamadermatology.com

Patients with psoriasis vs controls: Compared with controls,
patients with psoriasis had higher consumption of total and
simple carbohydrates, total fat, PUFAs, ω-6:ω-3 PUFA ratio,
cholesterol; lower consumption of protein, complex
carbohydrates, MUFAs, ω-3 PUFAs, fiber (P < .034). Among
patients with psoriasis: Higher MUFA consumption was a major
predictor of lower psoriasis severity (P < .001). Lower psoriasis
severity was associated with lower total energy, saturated fatty
acids, total PUFAs, ω-6 PUFAs, ω-6:ω-3 PUFA ratio, simple
carbohydrates and with higher ω-3 PUFAs, MUFAs, fiber,
complex carbohydrates (P < .007).

a

8

4

Quality assessed using Newcastle-Ottawa scale for case-control and cohort
studies (maximum score of 9), modified Newcastle-Ottawa scale for
cross-sectional studies (maximum score of 8).
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Table 2. Interventional Studies on the Effects of Gluten-Free Diet, Dietary Weight Reduction,
and Dietary Supplements on Psoriasis and Psoriatic Arthritis (PsA)
Source;
Country

Design

Study Population

Intervention

Control

Outcome Summary

Gluten-Free Diet
Michaëlsson
et al,14
2000;
Swedena

Prospective,
nonrandomized,
controlled

Psoriasis, some with PsA,
age 18-70 y, stable
psoriasis treatment for
at least 1 mo. Group 1:
elevated IgA AGA and/or
IgG AGA, n = 33. Group
2: normal IgA AGA and
IgG AGA, n = 6.

3-mo gluten-free
diet followed by 3
mo regular diet.
Decrease treatment
as tolerated.

Same
intervention

Between-group comparisons were not reported. Mean (SD)
psoriasis severity (PASI) improved in group 1 from 5.4 (4.5) to
3.6 (3.0) after gluten-free diet (P < .001); no improvement in
group 2 from 8.9 (6.4) to 10.2 (7.9) (P = .47). In group 1, PASI
improved in similar proportion of patients with psoriasis with
normal and abnormal duodenal biopsy (75% and 67%,
respectively). In group 1, 24% of patients decreased their
psoriasis treatment during gluten-free diet and 0% increased
treatment; in group 2, 0% decreased and 33% increased
treatment. After resuming regular diet, 60% of group 1 needed
to increase psoriasis treatment due to worsening disease vs 0%
of group 2

Michaëlsson
et al,15
2003;
Swedena

Prospective,
nonrandomized,
controlled

Psoriasis, some with PsA,
age 18-70 y, stable
psoriasis treatment for
at least 1 mo. Group 1:
elevated IgA AGA and/or
IgG AGA, n = 31. Group
2: normal IgA AGA and
IgG AGA, n = 6.

3-mo gluten-free
diet. Decrease
treatment as
tolerated. 3-mm
punch biopsy before
and after diet.

Same
intervention

Between-group comparisons were not reported. Group 1:
significant reduction in No. of CD4+ T lymphocytes in involved
epidermis (P = .03), No. of Ki67+ (proliferating) cells in
involved (P = .008) and noninvolved (P = .04) dermis, % tTG+
area in involved dermis (P = .008). Group 1: no significant
change in
No. of CD4+ T lymphocytes in involved dermis and noninvolved
epidermis and dermis, % CD1+ (Langerhans cells) area in
involved and noninvolved epidermis and papillary dermis, %
CD31/Q-Bend+ (endothelial cells) area in involved and
noninvolved dermis, % Ki67+ (proliferating cells) area in
involved and noninvolved epidermis, % tTG+ area in non
involved dermis. Group 2: no significant changes observed after
diet

De Bastiani
et al,16
2015;
Italy

Prospective,
uncontrolled

6-mo gluten-free
Plaque or guttate
psoriasis, some with PsA, diet
age 18-80 y, celiac
disease confirmed by
histologic analysis, some
receiving systemic
therapy. N = 9.

None

Uncontrolled data: Gluten-free diet led to significant
improvement in psoriasis severity (PASI 50 or PASI 75) in all
patients after 3 mo; the level of improvement was maintained
in 89% of patients at 6 mo

Dietary Weight Reduction
Naldi
et al,22
2014; Italy

Prospective,
assessorblind,
randomized,
controlled

Plaque psoriasis, PASI
>10, age 18-80 y, BMI
>25, not achieving
clearance with systemic
therapy after 4 wk
(continued during
study). Intervention:
n = 151; control:
n = 152.

20-wk hypocaloric
diet. Encouraged
aerobic exercise >40
min 3 times/wk.

Information
session on
utility of
weight
reduction for
psoriasis
control

Compared with controls, hypocaloric diet group had
significantly greater reduction in psoriasis severity and body
weight. Specifically, median PASI reduction, 48.0% (95% CI,
33.3%-58.3%) hypocaloric diet group vs 25.5% (95% CI,
18.2%-33.3%) controls (P = .02). PASI 50, 49.7% (95% CI,
41.7%-57.6%) of hypocaloric diet group vs 34.2% (95% CI,
26.7%-41.7%) of controls (P = .006). Median BMI reduction,
3.0% (95% CI, 2.4%-3.9%) hypocaloric diet group vs 1.9%
(95% CI, 1.4%-2.3%) controls (P = .002)

Di Minno
et al,62
2014; Italy

Prospective,
assessorblind,
randomized,
controlled

PsA, age >18 y, BMI >25,
failed traditional
DMARDs, starting tumor
necrosis factor blocker
therapy. Intervention:
n = 63; control: n = 63.

6-mo hypocaloric
diet

Self-managed
diet with
instruction to
eat healthily

Compared with controls, hypocaloric diet group had
significantly greater achievement of improved arthritis disease
severity and significantly greater weight loss. Specifically,
achievement of MDA, 43% of hypocaloric diet group vs 35% of
controls (HR, 1.85; 95% CI, 1.02-3.35; P = .04). Weight loss
>5% more likely in hypocaloric diet group vs controls
(HR, 3.23; 95% CI, 1.93-5.39; P < .001). Achievement of MDA
more likely with greater weight loss regardless of study group

Gisondi
et al,20
2008; Italy

Prospective,
investigatorblind,
randomized,
controlled

Active plaque psoriasis,
PASI ≥10, BSA ≥10%,
age ≥18 y, BMI 30-45.
Intervention: n = 30;
control: n = 31

24-wk hypocaloric
diet. Low-dose
cyclosporine (2.5
mg/kg daily).
Encouraged
moderate physical
exercise ≥40 min ≥4
times weekly.

No dietary
intervention.
Same
cyclosporine.
Same exercise
encouragement

Compared with controls, hypocaloric diet group had
significantly greater improvement in psoriasis severity and
significantly greater weight loss. Specifically, PASI 75, 67% of
hypocaloric diet group vs 29% of controls (P < .001). PASI 50,
87% of hypocaloric diet group vs 48% of controls (P < .001).
Mean (SD) PASI at week 24, 2.5 (6.3) hypocaloric diet group vs
8.1 (5.4) controls (P < .001). Mean (SD) BSA at week 24, 2.9%
(4.4%) hypocaloric diet group vs 7.5% (4.9%) controls
(P < .001). Mean (SD) weight loss, 7.0 (3.5) kg hypocaloric diet
group vs 0.2 (0.9) kg controls (P < .001)

Guida
et al,21
2014; Italy

Prospective,
assessorblind,
randomized,
controlled

6-mo hypocaloric,
Plaque psoriasis, age
ω-3–enriched diet
≥18 y, BMI >30,
receiving stable systemic
treatment for at least 5
mo (continued during
study). Intervention:
n = 22; control: n = 22.

No dietary
modification

Compared with controls, hypocaloric diet group had lower
psoriasis severity (PASI; P < .05), better dermatology quality of
life (DLQI; P < .05), and lower body weight (P < .05) after 6
mo. No significant difference between hypocaloric diet and
control groups in itch severity (VAS itch score) after 6 mo
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Table 2. Interventional Studies on the Effects of Gluten-Free Diet, Dietary Weight Reduction,
and Dietary Supplements on Psoriasis and Psoriatic Arthritis (PsA) (continued)
Source;
Country

Design

Study Population

Intervention

Control

Outcome Summary

Del Giglio
et al,27
2012; Italy

Prospective,
investigatorblind,
randomized,
controlled

Plaque psoriasis, PASI
>10 or >5 and
uncontrolled by topical
therapy, age ≥18 y, BMI
≥30, receiving
methotrexate and
obtained PASI 75 for 12
wk. Intervention: n = 22;
control: n = 20.

24-wk hypocaloric
diet. Methotrexate
discontinued.
Following diet,
12-wk follow-up
without dietary
modification.

No dietary
modification.
Methotrexate
discontinued.
Same
follow-up.

No significant differences between hypocaloric diet and control
groups in psoriasis severity (PASI) over 24-week diet or
12-week follow-up. Mean (SD) weight loss at 12 wk, 9% (2.4%)
hypocaloric diet group (P < .05), maintained at 24 wk
(P < .05), weight regained at 36 wk; no significant weight
change in controls

Kimball
et al,28
2012;
United
States

Prospective,
assessorblind,
randomized,
controlled

Plaque psoriasis, PASI
≥10, age ≥18 y, BMI >25,
eligible for
phototherapy.
Intervention: n = 20;
control: n = 10.

12-wk Ornish diet
(vegetarian, low fat,
n = 10) or South
Beach diet (low
carbohydrate,
n = 10). NB-UVB
phototherapy 3
times/wk.

No dietary
intervention.
Same
phototherapy.

No significant differences between Ornish diet, South Beach
diet, and control groups in improvement in psoriasis severity.
Specifically, PASI 75, 83% of Ornish diet group, 56% of South
Beach diet group, 38% of controls (P = .30). Mean PASI
improvement, 78% Ornish diet group, 72% South Beach diet
group, 71% controls. Mean weight loss, 8% Ornish diet group,
7% South Beach diet group, 0% controls (P < .05 for each diet
group vs controls)

Al-Mutairi
and Nour,19
2014;
Kuwait

Prospective,
randomized,
controlled

Psoriasis, PASI 20-50,
age >18 y, BMI 25-35,
receiving biologic
therapy. Intervention:
n = 131; control:
n = 131.

24-wk hypocaloric
diet

Usual diet

Compared with controls, hypocaloric diet group had
significantly greater reduction in psoriasis severity and body
weight. Specifically, PASI 75, 85.9% of hypocaloric diet group
vs 59.4% of controls (P < .001). Mean (SD) weight change,
−13.0 (1.2) kg hypocaloric diet group vs 1.5 (0.5) kg controls
(P < .001)

Jensen
et al,23
2013;
Denmark

Prospective,
randomized,
controlled

Plaque psoriasis, age >18 16-wk hypocaloric
diet
y, BMI >27, stable
psoriasis treatment ≥3
mo before study.
Intervention: n = 30;
control: n = 30.

Given
guidelines for
a healthy diet

No significant difference between hypocaloric diet and control
groups in psoriasis severity after 16 wk. Specifically, mean
between-group difference in PASI, −2.0 (95% CI, −4.1 to 0.1)
in favor of hypocaloric diet group (P = .06). Compared with
controls, hypocaloric diet group had significantly better
dermatology quality of life and significantly greater weight loss
after 16 wk. Specifically, mean between-group difference in
DLQI, −2.0 (95% CI, −3.6 to −0.3) in favor of hypocaloric diet
group (P = .02). Mean between-group difference in weight loss
15.4 (95% CI, 12.3 to 18.5) kg in favor of hypocaloric diet
group (P < .001). PASI improvement correlated with weight
loss in all participants (P < .001)

Ručević
et al,26
2003;
Croatia

Prospective,
controlled

Biopsy-confirmed
psoriasis inpatients, BSA
>30%, duration >10 y,
age 40-65 y.
Intervention: n = 42;
control: n = 40.

4-wk hypocaloric,
low-protein diet. No
coffee or alcohol.

Standard
hospital diet.
No alcohol.

Between-group comparisons were not reported. “Significant
improvement of clinical findings” in hypocaloric diet group
(effect measures not reported). Body weight did not change
significantly in either group.

Jensen
et al,24
2016;
Denmarkb

Prospective,
uncontrolled

Plaque psoriasis, age >18
y, BMI >27, stable
psoriasis treatment ≥3
mo before study. N = 56.

16-wk hypocaloric
diet. Following
hypocaloric diet,
48-wk maintenance
period with 1 meal
and 1 snack daily
replaced by
hypocaloric diet
formula products.

None

Uncontrolled data: Hypocaloric diet resulted in significant
improvement in psoriasis severity and dermatology quality of
life and significant weight loss after 16 wk; changes in psoriasis
severity and dermatology quality of life were maintained after
maintenance period. Specifically, mean PASI change, −2.3
(95% CI, −3.1 to −1.5) at week 16, −2.9 (95% CI, −3.9 to −1.9)
at week 64. Mean DLQI change, −2.3 (95% CI, −3.2 to −1.4) at
week 16 to −1.9 (95% CI, −3.0 to −0.9) at week 64. Mean
weight loss, 15.0 (95% CI, 13.4 to 16.6) kg at week 16,
10.1 (95% CI, 8.1 to 12.0) kg at week 64

Roongpisuthipong
et al,25
2013;
Thailand

Prospective,
uncontrolled

Plaque psoriasis, age
>18 y, BMI ≥30,
metabolic syndrome.
N = 10.

12-wk hypocaloric
diet. Low- or
moderate-potency
topical steroids.

None

Uncontrolled data: Hypocaloric diet resulted in 30.9%
improvement in psoriasis severity (PASI; P < .05), 62.5%
improvement in dermatology quality of life (DLQI; P < .01),
and 9.6% weight loss (P < .01) after 12 wk

Oral ω-3 Fatty Acid Fish Oil Supplementation
Kristensen
et al,12
2018;
Denmark

Prospective,
double-blind,
randomized,
placebocontrolled

PsA, age >18 y, not
receiving biologics or
oral steroids.
Intervention: n = 73;
control: n = 72.

24-wk
supplementation
with ω-3 fatty acids:
6 capsules
containing 1.5 g
EPA, 1.5 g DHA daily

Supplementation with
placebo: 6
capsules
containing 3 g
olive oil daily

No significant differences between ω-3 and control groups in
changes in any clinical outcome measures of skin or arthritis
disease severity. Compared with ω-6 group, ω-3 group had
greater reduction in the use of NSAIDs (P = .04) and
paracetamol (P = .04). Significant reductions in tender joint
count, DAS28-CRP, LEI, SPARCC, PASI in ω-3 group; significant
reduction in LEI in ω-6 group.

Søyland
et al,35
1993;
Norway

Prospective,
double-blind,
randomized,
placebocontrolled

Plaque psoriasis, BSA
>8%, age 19-74 y, no
systemic treatment 4 wk
before study, topical
treatments continued.
Intervention: n = 72;
control: n = 73.

4-mo
supplementation
with ω-3 fatty acids:
6 fish oil capsules
containing 3.1 g
EPA, 1.9 g DHA,
vitamin E daily.
Reduced dietary
saturated fatty acid
intake.

Supplementation with
ω-6 fatty
acids: 6 corn
oil capsules
with vitamin E
daily. Reduced
dietary
saturated
fatty acid
intake.

No significant differences between ω-3 and control groups in
changes in psoriasis severity. Specifically, mean target plaque
score (scaling, erythema, infiltration) changed identically
between ω-3 and control groups. Mean PASI did not change
significantly in either group. Patient-reported psoriasis severity
score (redness, scaling, itching, effect on daily living) did not
change significantly in either group.
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Table 2. Interventional Studies on the Effects of Gluten-Free Diet, Dietary Weight Reduction,
and Dietary Supplements on Psoriasis and Psoriatic Arthritis (PsA) (continued)
Source;
Country

Design

Study Population

Intervention

Control

Outcome Summary

Strong and
Hamill,36
1993;
United
Kingdom

Prospective,
double-blind,
randomized,
placebocontrolled

Plaque psoriasis
inpatients, no prior
systemic treatment or
phototherapy, no recent
topical steroid
treatment. Intervention:
n = 26; control: n = 25.

7-mo
supplementation
with ω-3 fatty acids:
12 fish oil/evening
primrose oil
capsules (Efamol
Marine) containing
216 mg EPA, 240
mg DHA daily;
started inpatient,
continued after
discharge

Supplementation with
placebo: 12
liquid paraffin
capsules daily

No significant differences between ω-3 and control groups in
psoriasis severity (percentage area involved, redness, scaling,
itch, overall impression) over 7 mo of supplementation

Madland
et al,33
2006;
Norway

Prospective,
double-blind,
randomized,
placebocontrolled

Polyarticular PsA (5 or
more swollen joints), no
intra-articular
glucocorticoids or
change in DMARDs for 4
wk before study, NSAIDs
and DMARDs continued.
Intervention: n = 22;
control: n = 21.

14-d
supplementation
with ω-3 fatty acids:
30 mL seal oil
containing 2.4 g
EPA, 1.1 g DPA, 2.6
g DHA daily.
Following
supplementation,
4-wk follow-up
without
supplementation.

Supplementation with
ω-6 fatty
acids: 30 mL
soy oil daily.
Same
follow-up

No significant differences between ω-3 and ω-6 groups in
clinical outcome measures of skin or arthritis disease severity
at the end of supplementation or after the follow-up period.
Patient’s global assessment VAS improved significantly at week
6 in ω-3 group (P < .01). No. of swollen joints decreased at
week 6 in ω-3 group (P < .05). No. of tender joints decreased
at week 6 in both groups (P < .05). PASI unchanged in both
groups after treatment.

Veale
et al,34
1994;
United
Kingdom

Prospective,
double-blind,
randomized,
placebocontrolled

PsA, age 18-76 y,
NSAID/paracetamol dose
stable for 1 mo before
study. Intervention:
n = 19; control: n = 19.

9-mo
supplementation
with ω-3 fatty acids:
12 fish oil/evening
primrose oil
capsules (Efamol
Marine) containing
240 mg EPA, 132
mg DHA, vitamin E
daily. Subsequently
crossed over to
placebo for 3 mo.

12-mo
supplementation with
placebo: 12
liquid paraffin
with vitamin E
capsules daily

No significant differences between ω-3 and control groups in
arthritis disease severity (grip strength, No. of active joints,
Ritchie articular index, duration of morning stiffness, NSAID
intake) or skin disease severity (BSA, investigator disease
severity VAS, skin itch VAS) after 6, 9, or 12 mo

Bjørneboe
et al,38
1988;
Norway

Prospective,
double-blind,
randomized,
placebocontrolled

Psoriasis, age 17-72 y,
no topical steroids 2 mo
before study.
Intervention: n = 15;
control: n = 15.

8-wk
supplementation
with ω-3 fatty acids:
10 fish oil capsules
(MaxEPA)
containing 1.8 g
EPA, 1.2 g DHA,
vitamin A, vitamin E,
vitamin D daily

Supplementation with
placebo: 10
olive oil
capsules daily

Between-group comparisons were not reported. Clinical score
(erythema, infiltration, desquamation) and BSA did not change
significantly in ω-3 or control groups.

Bittiner
et al,39
1988;
England

Prospective,
double-blind,
randomized,
placebocontrolled

Plaque psoriasis, not
receiving systemic
treatment, topical
treatment continued.
Intervention: n = 14;
control: n = 14.

12-wk
supplementation
with ω-3 fatty acids:
10 fish oil capsules
(MaxEPA)
containing 1.8 g
EPA, 1.2 g DHA daily

Supplementation with
placebo: 10
olive oil
capsules daily

Compared with controls, ω-3 group had significantly greater
improvement in itch at week 8 and erythema at weeks 8 and
12 (P < .05). No significant differences between groups in
improvement in scaling or BSA.

Gupta
et al,37
1990;
United
States

Prospective,
double-blind,
randomized,
placebocontrolled

Plaque psoriasis, BSA
>10%, adults, no
systemic treatment for 4
wk or topical treatment
for 2 wk before study.
Intervention: n = 10;
control: n = 15.

9-wk
supplementation
with ω-3 fatty acids:
30 fish oil capsules
(Max-EPA)
containing 5.4 g
EPA, 3.6 g DHA
daily.
Betamethasone
diproprionate cream
applied twice daily
weeks 1-3.

Supplementation with
placebo: 30
olive oil
capsules daily.
Same topical
treatment
weeks 1-3.

No significant differences between ω-3 and control groups in
psoriasis improvement after topical treatment or in time to
worsening of psoriasis to pretreatment severity. Specifically,
equivalent improvement in psoriasis severity (scale, erythema,
thickness, BSA) between groups after 3-wk topical steroid
treatment. Mean (SD) time from termination of topical steroid
treatment to worsening of psoriasis to pretreatment severity
4.9 (0.5) wk ω-3 group vs 4.5 (0.3) wk controls (P = .4).

Gupta
et al,30
1989;
United
States

Prospective,
double-blind,
randomized,
placebocontrolled

Psoriasis, BSA 10%-50%,
adults, skin type II or III,
no systemic treatment
for 4 wk or topical
treatment for 2 wk
before study.
Intervention: n = 9;
control: n = 11.

15-wk
supplementation
with ω-3 fatty acids:
20 fish oil capsules
(Max-EPA)
containing 3.6 g
EPA, 2.4 g DHA
daily. UVB
phototherapy twice
weekly weeks 3-11.

Supplementation with
placebo: 20
olive oil
capsules daily.
Same
phototherapy
weeks 3-11.

Compared with controls, ω-3 group had significantly greater
improvement in psoriasis severity. Specifically, change from
baseline in scale, −35% ω-3 group vs 9% controls (P = .008);
erythema, −43% ω-3 group vs 0% controls (P = .02); thickness,
−48% ω-3 group vs 7% controls (P = .006); BSA, −46% ω-3
group vs 32% controls (P < .001).
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Table 2. Interventional Studies on the Effects of Gluten-Free Diet, Dietary Weight Reduction,
and Dietary Supplements on Psoriasis and Psoriatic Arthritis (PsA) (continued)
Source;
Country

Design

Study Population

Intervention

Control

Outcome Summary

Danno and
Sugie,66
1998; Japan

Prospective,
open-label,
randomized,
controlled

Plaque psoriasis,
moderate disease, age
25-78 y, topical
treatment continued.
Intervention: n = 20;
control: n = 20.

12-wk
supplementation
with ω-3 fatty acids:
EPA capsules
(ReEPA) containing
1.8 g EPA daily.
Low-dose etretinate
(20 mg daily).

No
supplementation. Same
etretinate.

Compared with controls, ω-3 group had significantly greater
and faster reduction in psoriasis severity. Specifically, ≥75%
reduction in clinical scorec (erythema, induration,
desquamation) in 45% of ω-3 group vs 15% of controls
(P < .05). ≥50% reduction in clinical score in 65% of ω-3 group
vs 55% of controls (NS). Mean (SD) duration to 50% reduction
in clinical score, 5.1 (1.5) wk ω-3 group vs 7.6 (3.4) wk
controls (P < .05).

Balbás
et al,67
2011; Spain

Prospective,
open-label,
nonrandomized,
controlled

Plaque psoriasis, PASI
≤10, age 18-70 y, no
systemic/biologic
treatment for 4 wk or
topical treatment for 2
wk before study.
Intervention: n = 15;
control: n = 15.

8-wk
supplementation
with ω-3 fatty acids:
2 Oravex capsules
containing 560 mg
EPA, 80 mg DHA, 15
mg zinc, 55 μg
selenium daily.
Topical tacalcitol.

No
supplementation. Topical
tacalcitol.

Compared with controls, ω-3 group had significantly greater
improvement in psoriasis severity, psoriatic nail severity,
dermatology quality of life, pruritus, and scalp psoriasis.
Specifically, mean PASI reduction, 6.8 ω-3 group vs 3.53
controls (P < .001). Mean NAPSI reduction, 1.23 ω-3 group vs 0
controls (P = .048). Mean DLQI reduction, 6.7 ω-3 group vs 3.0
controls (P = .006). Presence of pruritus reduction, 80% ω-3
group vs 40% controls (P < .001). Mean severity of scalp
psoriasis reduction, 0.6 ω-3 group vs 0 controls (P = .004).

Lassus
et al,68
1990;
Finland

Prospective,
uncontrolled

Plaque psoriasis, 43%
with PsA, age 23-68 y,
not receiving systemic or
topical treatment.
N = 80.

None
8-wk
supplementation
with ω-3 fatty acids:
6 capsules
containing 1.12 g
EPA, 0.76 g DHA
daily

Uncontrolled data: Supplementation with ω-3 resulted in
significant improvement in skin and arthritis disease severity
after 8 wk. Specifically, mean PASI, 3.56 at baseline, 1.98 at 4
wk (P < .001), 1.24 at 8 wk (P < .001). Mean pruritus, scaling,
induration, and erythema scores improved significantly from
baseline at weeks 4 and 8 (P < .01). Patient-reported severe
joint pain in 53% of patients with PsA at baseline, 6% at week
8 (P < .001).

Kragballe
and Fogh,69
1989;
Denmark

Prospective,
open-label,
uncontrolled

Plaque psoriasis, no
systemic treatment for 2
mo or topical treatment
for 2 wk before study.
N = 30.

None
4-mo
supplementation
with ω-3 fatty acids:
30 mL fish oil
(MaxEPA)
containing 5.4 g
EPA, 4.8 g DHA,
vitamins A, D, and E
daily. 100 μg
selenium daily.
Low-fat diet.

Uncontrolled data: Supplementation with ω-3 resulted in
“moderate or excellent improvement” in psoriasis severity in
58% of patients, “mild improvement” in 19%, and “no change”
in 23% after 4 mo (degree of improvement vs baseline graded
at each visit, categories not defined)

Kettler
et al,70
1988;
United
States

Prospective,
open-label,
uncontrolled

Plaque psoriasis
(n = 24), generalized
pustular psoriasis
(n = 1), palmoplantar
pustulosis (n = 1), age
19-61 y, psoriasis
treatment continued.
N = 26.

None
6-8 wk
supplementation
with ω-3 fatty acids:
18 fish oil capsules
(Max EPA)
containing 3.2 g
EPA, 2.2 g DHA daily

Uncontrolled data: Supplementation with ω-3 resulted in
minimal improvement in psoriasis severity in 35% of patients,
no change in 43%, and “mild worsening” in 22% after 6-8 wk
(minimal improvement is 1 point improvement in erythema,
scale, or thickness on 4-point scale)

Kragballe,71
1989;
Denmark

Prospective,
open-label,
uncontrolled

Plaque psoriasis, age
12-69 y, no systemic
treatment for 2 mo or
topical treatment for 2
wk before study. N = 18.

None
4-mo
supplementation
with ω-3 and ω-6
fatty acids: 12
capsules (Super
Gamma-Oil Marine)
containing 540 mg
EPA, 360 mg DHA,
3.36 g LA, 960 mg
GLA, vitamin E daily.
100 μg selenium
daily. Low-fat diet.

Uncontrolled data: Supplementation with ω-3 and ω-6 resulted
in “moderate or excellent improvement” in psoriasis severity in
59% of patients, “mild improvement” in 23%, and “no change”
in 18% after 4 mo (degree of improvement vs baseline graded
at each visit, categories not defined)

Ziboh
et al,72
1986;
United
States

Prospective,
open-label,
uncontrolled

Psoriasis, BSA >10%,
13% with PsA, adults, no
systemic treatment for 2
mo or topical treatment
for 2 wk before study.
N = 15.

None
8 wk
supplementation
with ω-3 fatty acids:
60-75 g fish oil
concentrate
(Max-EPA)
containing 11-14 g
EPA, 7-9 g DHA
daily. Exclusion of
fats and oils from
diet

Uncontrolled data: Supplementation with ω-3 resulted in
significant reduction in erythema (P < .02), scaling (P < .001),
and thickness (P < .004) after 8 wk; BSA unchanged from
baseline

Maurice
et al,73
1987;
United
Kingdom

Prospective,
uncontrolled

Plaque psoriasis, BSA
5%-60%, 20% with PsA,
age 25-65 y,
long-standing disease
requiring systemic
treatment. N = 10.

None
≥6-wk
supplementation
with ω-3 fatty acids:
≤50 mL fish oil
(Max-EPA)
containing ≤12 g
EPA, unknown
quantity DHA daily.
Low-fat diet.

Uncontrolled data: Supplementation with ω-3 resulted in
“slight to moderate improvement” in psoriasis severity
(redness, scaling) in 80% of patients after 6 wk; “improvement”
was maintained for the duration of treatment
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Table 2. Interventional Studies on the Effects of Gluten-Free Diet, Dietary Weight Reduction,
and Dietary Supplements on Psoriasis and Psoriatic Arthritis (PsA) (continued)
Source;
Country
Kojima
et al,74
1989; Japan

Design

Study Population

Intervention

Prospective,
uncontrolled

Psoriasis, age 22-75 y,
topical treatment
continued. N = 9.

None
6-mo
supplementation
with ω-3 fatty acids:
3.6 g EPA daily

Control

Outcome Summary
Uncontrolled data: Supplementation with ω-3 resulted in
“clinically significant improvement” in psoriasis severity
(erythema, scaling, thickness) in 86% of patients after 6 mo

Intravenous ω-3 Fatty Acid Fish Oil Supplementation
Mayser
et al,40
1998; Czech
Republic,
Germany,
Austria,
Poland,
Slovakia

Prospective,
double-blind,
randomized,
placebocontrolled

Plaque psoriasis
inpatients, PASI ≥15,
18% with PsA, age 18-80
y, no systemic treatment
for 3 mo or topical
treatment for 7 d before
study. Intervention:
n = 43; control: n = 40.

14-d treatment with
ω-3 lipid emulsion
(Omegavenous) 100
mL IV twice daily
(4.2 g EPA, 4.2 g
DHA daily)

Treatment
with ω-6 lipid
emulsion
(Lipovenous)
100 mL IV
twice daily

Compared with ω-6 group, ω-3 group had significantly greater
reduction in psoriasis severity. Specifically, mean (SD) PASI
reduction, 11.2 (9.8) ω-3 group vs 7.5 (8.8) ω-6 group
(P = .048). PASI 50, 37% of ω-3 group vs 23% of ω-6 group.
Mean (SD) self-assessed severity VAS scorec reduction,
17.5 (19.3) ω-3 group vs 10.4 (18.4) ω-6 group.

Grimminger
et al,41
1993;
Germany

Prospective,
double-blind,
randomized,
placebocontrolled

Acute guttate psoriasis
inpatients, BSA >10%,
age 21-65 y, not
receiving systemic
treatment, no topical
treatment for 5 d before
study. Intervention:
n = 9; control: n = 11.

10-d treatment with
ω-3 lipid emulsion
(Omegavenous) 50
mL IV twice daily
(2.1 g EPA, 2.1 g
DHA daily)

Treatment
with ω-6 lipid
emulsion
(Lipovenous)
50 mL IV
twice daily

Compared with ω-6 group, ω-3 group had greater improvement
in all psoriasis severity measures (erythema, infiltration,
desquamation, patient-reported subjective score [daily life
impairment, pruritus, burn, pain]) (P < .05). All psoriasis
severity measures improved in both groups.

Siddiqui and Prospective,
Al-Khawajah,44 double-blind,
1990; Saudi randomized,
placeboArabia
controlled

Biopsy-confirmed
psoriasis, PASI >15,
adults, no systemic or
topical treatment for 4 wk
before study. Intervention: n = 20; control:
n = 21.

12-wk supplementation with vitamin D:
1 capsule containing
1 μg alfacalcidol daily

Supplementation with
placebo: 1
capsule daily

No significant differences between vitamin D and control groups in
improvement in psoriasis severity. Specifically, slight
improvement (<33% PASI reduction) in 45% of vitamin D group
vs 38% of controls. No change or increase in PASI, 55% of
vitamin D group vs 62% of controls

Gaál
et al,45
2009;
Hungary

Prospective,
open-label,
nonrandomized,
controlled

PsA, treated with methotrexate 10 mg weekly and
NSAIDs for ≥3 mo before
study. Intervention: osteopenia, n = 10; control:
no osteopenia, n = 9.

6-mo supplementation with vitamin D:
0.5 μg alfacalcidol
daily

No
supplementation

Between-group comparisons were not reported. Significant improvement in arthritis disease severity (DAS28) in vitamin D group
(P = .048); no significant change in controls. No significant improvement in skin disease severity (PASI, patient’s global assessment VAS) in either group.

Perez
Prospective,
et al,47
open-label,
1996; United uncontrolled
States

Plaque psoriasis or EP,
BSA ≥15%, age 19-76 y,
not responding to ≥1
standard treatment, no
systemic treatment or
phototherapy for 30 d or
topical treatment for 14 d
before study. N = 85.

6-mo to 3-y supplementation with vitamin D: mean (SD)
dose 2.1 (0.8) μg
calcitriol (Rocaltrol)
daily (dose adjusted
based on urinary calcium level). Dietary
calcium limited to
800 mg daily.

None

Uncontrolled data: Supplementation with vitamin D resulted in
significant improvement in psoriasis severity after 6 mo and 3 y.
Specifically, mean (SD) PASI, 18.4 (1.0) at baseline, 9.7 (0.8) at
month 6, 7.0 (1.3) at year 3 (P < .001). Mean (SD) global severity
score (erythema, thickness, scaling), 7.7 (1.2) at baseline, 3.2
(1.0) at year 3 (P < .001). Erythema, scaling, thickness each decreased at month 6 (P < .001) and year 3 (P < .001).

Morimoto
et al,50
1986; Japan

Prospective,
open-label,
uncontrolled

Psoriasis, age 23-63 y, all
psoriasis treatments
stopped before study.
N = 17.

None
6-mo supplementation with vitamin D: 1
μg alfacalcidol
(Alfarol) daily

Smith
Prospective,
et al,48
uncontrolled
1988; United
States

Psoriasis, moderate to
extensive disease
refractory to standard
treatment, age 22-63 y,
no psoriasis treatment for
2 wk before study.
N = 14.

≤1-y supplementation with vitamin D:
capsules (Rocaltrol)
containing 0.5-2.0
μg calcitriol daily
(dose adjusted based
on urinary and serum
calcium levels). Dietary calcium limited
to 800 mg daily.

None

Uncontrolled data: Supplementation with vitamin D resulted in
>25% improvement in psoriasis severity (lesion size, erythema,
scaling, pruritus) in 71% of patients, >50% improvement in 50%,
and >75% improvement in 50%

Huckins
Prospective,
et al,63
open-label,
1990; United uncontrolled
States

PsA, age 18-70 y, no
change in treatment for 3
mo before or during study
(changes in NSAIDs or
steroids permitted).
N = 10.

6-mo supplementation with vitamin D:
0.5-2.0 μg calcitriol
(Rocaltrol) daily
(dose adjusted based
on urinary and serum
calcium levels)

None

Uncontrolled data: Supplementation with vitamin D resulted in
significant improvement in tender joint count (P < .01) and
physician global assessment of arthritis activity (P < .05) after
6 mo; no significant change in patient global assessment, grip
strength, or patient-reported pain and physical activity scores
(AIMS)

Vitamin D Supplementation

Uncontrolled data: Supplementation with vitamin D resulted in
effective response in 76% of patients after 6 mo (effective response is “moderate improvement,” “marked improvement,” or
“complete remission” in psoriasis severity)

(continued)

Additional studies are needed to determine whether it is the type
of diet and/or weight reduction that reduces psoriasis severity, the
associated mechanisms, the amount of weight reduction needed for
942

clinical response, how to implement dietary recommendations effectively, and the role of exercise in conjunction with dietary weight
reduction.
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Table 2. Interventional Studies on the Effects of Gluten-Free Diet, Dietary Weight Reduction,
and Dietary Supplements on Psoriasis and Psoriatic Arthritis (PsA) (continued)
Source;
Country

Design

Study Population

Intervention

Finamor
et al,46
2013; Brazil

Prospective,
open-label,
uncontrolled

Psoriasis, age >18 y, no
change in treatments.
N = 9.

None
6-mo
supplementation
with vitamin D: 1.75
mL sunflower oil
solution containing
35 000 IU
cholecalciferol daily.
Low-calcium diet
with daily hydration
≥2.5 L

Uncontrolled data: Supplementation with vitamin D resulted in
significant improvement in psoriasis severity (PASI) in all
patients after 6 mo (P = .002). Lower psoriasis severity (PASI)
was
correlated with higher serum vitamin D levels (P = .001)

el-Azhary
et al,75
1993;
United
States

Prospective,
uncontrolled

Psoriasis, BSA >25%, age
28-65 y, no psoriasis
treatment for 4 wk
before study
(corticosteroid cream
not stronger than
triamcinolone, 0.05%,
permitted). N = 8.

6-mo
supplementation
with vitamin D:
0.5-2.0 μg calcitriol
(Rocaltrol) daily
(dose adjusted
based on clinical
response). Dietary
calcium limited to
800 mg daily.

None

Uncontrolled data: Supplementation with vitamin D resulted in
“marked improvement” in scale, erythema, and thickness in
13% of patients, “moderate improvement” in 13%, “mild
improvement” in 38%, and “no improvement” in 38% after 6
mo; supplementation resulted in “marked improvement” in
area of involvement in 13% of patients, “mild improvement” in
13%, and “no improvement” in 75% after 6 mo

Takamoto
et al,49
1986; Japan

Prospective,
uncontrolled

Psoriasis, duration >6
mo, refractory to
treatment, age 37-63 y,
topical steroids
continued. N = 7.

None
6-mo
supplementation
with vitamin D: 1 μg
alfacalcidol (Alfarol)
daily

Uncontrolled data: Supplementation with vitamin D resulted in
complete remission of psoriasis in 29% of patients, marked
improvement in 29%, and no change in 43% after 6 mo
(complete remission is complete flattening of plaques, area
improved ≥95%; marked improvement is nearly
complete flattening of plaques, area improved
50%-90%)

Kharaeva
Prospective,
et al,54
double-blind,
2009; Russia randomized,
placebocontrolled

Severe EP or PsA
inpatients, adults.
Intervention:
n = 14 (EP),
n = 15 (PsA). Control:
n = 14 (EP),
n = 15 (PsA).

30-d
supplementation
with selenium: 4 soy
lecithin capsules
containing 48 μg
selenium aspartate,
50 mg coenzyme
Q10 (ubiquinone
acetate), 50 mg
vitamin E
(α-tocopherol) daily.
EP: IV
corticosteroids,
injections of
desensitizers,
keratoplastic and
corticosteroid
ointments. PsA: Oral
corticosteroids,
desensitizers,
NSAIDs,
painkillers.

Supplementation with
placebo: 4
soy lecithin
capsules daily.
EP: Same
treatment.
PsA: Same
treatment.

Compared with PsA and EP controls, PsA and EP selenium
groups had significantly lower overall psoriasis severity after
supplementation. Specifically, mean (SD) severity scorec
(plaque desquamation, plaque hyperemia, plaque inflammation,
nail dystrophy, joint pain) at day 30, 1.9 (0.1) PsA selenium
group vs 6.8 (0.2) PsA controls (P < .001); 4.0 (0.1) EP
selenium group vs 6.2 (0.1) EP controls (P < .05). Mean (SD)
PASI at day 30, 16 (6) PsA selenium group vs 29 (10) PsA
controls (P value not reported); 19 (4) EP selenium group vs
30 (5) EP controls (P < .05)

Serwin
et al,56
2006;
Poland

Prospective,
double-blind,
randomized,
placebocontrolled

Psoriasis inpatients, age
18-50 y, skin type II or
III, nonsmokers for ≥2 y,
no selenium
supplementation for 6
mo or topical treatment
for 1 wk before study.
Intervention: n = 19,
control: n = 18.

4-wk
supplementation
with selenium: 2
selenomethionine
tablets containing
200 μg selenium
daily. NB-UVB
phototherapy 5
times weekly.
Following
treatment, 4-week
follow-up without
supplementation or
phototherapy.

Supplementation with
placebo: 2
tablets daily.
Same
phototherapy.
Same
follow-up.

No significant differences between selenium and control groups
in improvement in psoriasis severity at the end of
supplementation or after the follow-up period. Specifically,
PASI 75 at wk 4, 47% of selenium group vs 56% of controls
(P > .05). PASI 75 at wk 8, 58% of selenium group vs 56% of
controls (P > .05). Mean (SD) PASI at baseline, wk 4, wk 8,
13.02 (6.25), 3.59 (2.27), 2.82 (2.48) selenium group vs
12.37 (4.71), 2.34 (1.70), 2.23 (1.49) controls (significant
reduction from baseline in both groups; P values not reported).

Serwin
et al,55
2003;
Poland

Prospective, Plaque psoriasis, age
double-blind, 18-50 y. Intervention:
randomized, n = 11; control: n = 11.
placebocontrolled

4-wk
supplementation
with selenium: 2
selenomethionine
tablets containing
200 μg selenium
daily. 5% salicylic
acid ointment
and 0.1%-0.3%
dithranol ointment

Supplementation with
placebo: 2
tablets daily.
Same topical
treatment.

No significant differences between selenium and control groups
in proportion of patients with improved psoriasis severity after
2 or 4 wk. Specifically, PASI 50 at wk 2, 54% of selenium group
vs 82% of controls (P > .05). PASI 75 at week 4, 45% of
selenium group vs 82% of controls (P > .05).

Control

Outcome Summary

Selenium Supplementation

(continued)
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Table 2. Interventional Studies on the Effects of Gluten-Free Diet, Dietary Weight Reduction,
and Dietary Supplements on Psoriasis and Psoriatic Arthritis (PsA) (continued)
Source;
Country
Harvima
et al,52
1993;
Finland

Design

Study Population

Intervention

Control

Outcome Summary

Prospective,
open,
uncontrolled

Plaque psoriasis, age
21-52 y, no systemic
treatment for 2 y or
topical treatment for 2
wk before study. N = 7.

6-wk
supplementation
with selenium: 8
selenomethionineyeast tablets
containing 400 μg
selenium daily.
Following
supplementation,
3-mo follow-up
without
supplementation.

None

Uncontrolled data: Supplementation with selenium resulted in
“some improvement” in psoriasis severity in 29% of patients,
“slight worsening” in 29%, and “severe worsening” in 14%
after 6 wk; “overall clinical condition remained unchanged”
after 3-mo follow-up

Psoriasis, age >12 y,
using various topical
treatments.
Intervention: n = 36;
control: n = 35

3-wk treatment with
vitamin B12: 1000
μg vitamin B12 IM 5
d weekly. Following
treatment, 3 wk
follow-up without
treatment.

Treatment
with placebo:
placebo IM 5
d weekly.
Same
follow-up.

No differences between vitamin B12 and control groups in
proportion of patients with improved psoriasis severity after 3
or 6 wk (reports that lack of treatment effect is “evident
without formal statistical analysis”). Specifically, “substantially
improved or clear” in 8% of vitamin B12 group vs 14% of
controls at week 3; 61% of vitamin B12 group vs 60% of
controls at week 6

Psoriasis, age 21-68 y.
N = 34.

≥10-d treatment
with vitamin B12:
1000 μg vitamin B12
IM daily. Following
treatment, ≥2 mo
maintenance period
with unspecified
dose of vitamin B12.

None

Uncontrolled data: Treatment with vitamin B12 resulted in
changes in psoriasis severity of “eruption involuted” in 32% of
patients, “improved 75%-80%” in 29%, “slowly improving” in
18%, “no results” in 15%, and “slight recurrence after
treatment stopped, resumed with good results” in 15%

12-wk
supplementation
with micronutrients:
1 tablet (Immunace)
containing folic acid,
magnesium, iron,
zinc, copper,
manganese,
selenium,
chromium, iodine,
vitamins A, D, E, K,
C, B1, B2, B3, B6, B12
daily. Methotrexate
7.5-15 mg weekly.

No
supplementation. Same
methotrexate
therapy.

Compared with controls, micronutrient group had significantly
greater reduction in psoriasis severity (PASI) after
supplementation (P = .045). PASI 75, 65% of micronutrient
group vs 35% of controls (P = .08). Mean (SD) PASI improved
from 31.80 (10.57) at baseline to 5.50 (3.82) at week 12
micronutrient group (P = .001); from 30.23 (10.87) to
10.86 (9.84) controls (P = .001)

Vitamin B12 Supplementation
Baker and
Comaish,58
1962;
United
Kingdom

Prospective,
double-blind,
randomized,
placebocontrolled

Ruedemann,57 Open,
uncontrolled
1954;
United
States

Micronutrient Supplementation
Yousefzadeh
et al,11
2017; Iran

Prospective,
double-blind,
randomized,
controlled

Biopsy-confirmed
psoriasis, PASI >10, age
20-50 y, no
methotrexate for 2 mo
before study.
Intervention: n = 17;
control: n = 17.

Abbreviations: AGA, antigliadin antibodies; AIMS, Arthritis Impact
Measurement Scales; BMI, body mass index, calculated as weight in kilograms
divided by height in meters squared; BSA, body surface area; DAS28, 28-joint
Disease Activity Score; DAS28-CRP, 28-joint Disease Activity Score (C-reactive
protein); DHA, docosahexaenoic acid; DLQI, Dermatology Life Quality Index;
DMARDs, disease-modifying antirheumatic drugs; DPA, docosapentaenoic acid;
EP, erythrodermic psoriasis; EPA, eicosapentaenoic acid; GLA, γ-linolenic acid;
HR, hazard ratio; IM, intramuscular; IV, intravenous; LA, linoleic acid; LEI, Leeds
Enthesitis Index; MDA, minimal disease activity; NAPSI, Nail Psoriasis Severity
Index; NB-UVB, narrowband UVB;

Weight reduction should always be recommended for overweight patients because it has beneficial effects on other health outcomes including reduction of cardiometabolic and certain cancer risks.
At this time, data are lacking on dietary weight reduction in normalweight patients with psoriasis.

Recommendation 2: Dietary Weight Reduction in Psoriasis
• In overweight or obese adults with psoriasis (BMI, ⱖ25), we
strongly recommend dietary weight reduction with a hypocaloric
diet as an adjunctive intervention to standard medical therapies
for psoriasis.
944

NS, nonsignificant; NSAIDs, nonsteroidal anti-inflammatory drugs; PASI,
Psoriasis Area and Severity Index; plus sign, positive; SPARCC, Spondyloarthritis
Research Consortium of Canada Enthesitis Index; tTG, tissue transglutaminase;
VAS, visual analogue scale.
a

These 2 articles report different outcome measures from the same study.

b

Follow-up of subset of patients from Jensen et al,23 2013; intervention group
entered maintenance period, control group first crossed over to 16-week
hypocaloric diet then entered maintenance period.

c

Higher score corresponds to greater disease severity.

• This strong recommendation (strength 1) is based on level A evidence, with consistent results among included studies and agreement with systematic reviews and meta-analysis.4,9,19-23

Question 3: Are Any Dietary Supplements Helpful
in Psoriasis?
Dietary supplements are used by a significantly higher proportion
of patients with psoriasis than those without psoriasis.29 Many
patients with psoriasis believe that supplementation can improve
their disease severity.5 Patients most frequently report improvement from supplementation with fish oil and vitamin D.5 However, patients should consult with a health care practitioner
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Table 3. Dietary Recommendations for Psoriasis and Psoriatic Arthritis
Recommended
or Not

Strength of
Recommendation

Recommendation

Level of
Evidencea Sourceb

Psoriasis
1. Gluten-free diet
⻬⻬⻬
⻬⻬

X

2. Dietary weight
reduction
⻬⻬⻬

3a. Fish oil
supplementation
X

…

3b. Vitamin D
supplementation
X
3c. Selenium
supplementation
X
…

3d. Vitamin B12
supplementation
X
3e. Micronutrient
supplementation
…

4. Specific foods,
nutrients, or dietary
patterns
⻬

⻬

In adults with psoriasis with confirmed celiac disease, we strongly recommend
a gluten-free diet.
Only in adults with psoriasis who test positive for serologic markers of gluten
sensitivity, we recommend a 3-mo trial of a gluten-free diet as an adjunctive
intervention to standard medical therapies for psoriasis.

Rubio-Tapia et al,17
2013
De Bastiani et al,16
2015; Michaëlsson
et al,15 2003;
Michaëlsson et al,14
2000

1

A

2A

B

1

A

Al-Mutairi and
Nour,19 2014;
Gisondi et al,20
2008; Guida et al,21
2014; Jensen
et al,23 2013; Naldi
et al,22 2014

Based on low-quality evidence, adults with psoriasis may consider a trial of a
Mediterranean diet and consuming extra virgin olive oil as the main culinary
lipid, ≥2 servings of vegetables daily, ≥3 servings of fruits daily, legumes ≥3
times weekly, fish or seafood ≥3 times weekly, tree nuts ≥3 times weekly, or
sofrito sauce (tomatoes, onions, garlic, olive oil) ≥2 times weekly.
Based on low-quality evidence, adults with psoriasis may consider a trial of
consuming more ω-3 PUFAs, monounsaturated fatty acids, fiber, or complex
carbohydrates and consuming less total energy, saturated fatty acids, total
PUFAs, ω-6 PUFAs, ω-6:ω-3 PUFA ratio, or simple carbohydrates.

2B

C

Barrea et al,60 2015

2B

C

Barrea et al,61 2015

In overweight or obese adults with psoriatic arthritis (BMI ≥25), we recommend
dietary weight reduction with a hypocaloric diet as an adjunctive intervention to
standard medical therapies for psoriatic arthritis.

2A

B

Di Minno et al,62
2014

We do not recommend universal screening for serologic markers of gluten
sensitivity among adults with psoriatic diseases because of a high rate of
false-positive results. Based on recommendations from the American College of
Gastroenterology, patients who are candidates for screening include those with
a first-degree relative with celiac disease or those with active gastrointestinal
symptoms.

In overweight or obese adults with psoriasis (BMI ≥25), we strongly recommend
dietary weight reduction with a hypocaloric diet as an adjunctive intervention to
standard medical therapies for psoriasis.

We do not recommend oral fish oil supplementation for treatment of psoriasis in
adults because oral fish oil was not effective at the examined doses and
durations.
Because evidence is limited regarding the effectiveness of intravenous fish oil
supplementation on psoriasis in adults, a recommendation cannot be made at
this time.

We do not recommend oral vitamin D supplementation for prevention or
treatment of psoriasis in adults with normal vitamin D levels.

We do not recommend selenium supplementation for treatment of plaque
psoriasis in adults.
Because evidence is limited regarding the effectiveness of selenium
supplementation on erythrodermic psoriasis in adults, a recommendation cannot
be made at this time.

We do not recommend vitamin B12 supplementation for treatment of psoriasis
in adults.

Because evidence is limited regarding the effectiveness of combination
micronutrient supplementation on psoriasis in adults, a recommendation cannot
be made at this time.

Psoriatic Arthritis
5. Dietary
interventions
⻬⻬

(continued)
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Table 3. Dietary Recommendations for Psoriasis and Psoriatic Arthritis (continued)
Recommended
or Not
⻬⻬

…

X

Recommendation
In adults with psoriatic arthritis, we recommend a trial of oral vitamin D
supplementation (0.5 μg alfacalcidol or 0.5-2.0 μg calcitriol daily) as an
adjunctive intervention to standard medical therapies for psoriatic arthritis.
Because evidence is limited regarding the effectiveness of selenium
supplementation on psoriatic arthritis in adults, a recommendation cannot
be made at this time.
We do not recommend fish oil supplementation for treatment of psoriatic
arthritis in adults.

Level of evidence determines the grade of recommendation.13 Level of
evidence “A” refers to high-quality, patient-oriented evidence, which leads to a
“strong recommendation” (strength of recommendation 1). Level of evidence

before taking supplements because many supplements have
adverse effects or contraindications.
ω-3 Fatty Acids (Fish Oil)

Polyunsaturated fatty acids (PUFAs), a type of dietary fatty acids,
include ω-3 and ω-6 PUFAs. The ω-6 PUFAs arachidonic acid
and linoleic acid are metabolized into leukotriene B4 (LTB4); LTB4
is an inflammatory mediator that is elevated in psoriatic plaques.30,31
In contrast, metabolites of ω-3 PUFAs oppose the pro-inflammatory effects of LTB4.32
Whereas the typical Western diet has an ω-6:ω-3 ratio
of 15-20:1, an ideal ratio of 1.8:1 is recommended by an international panel of experts. 31 This ratio is similar to that found
throughout human history. Notably, lower psoriasis incidence is
seen in regions with a higher relative intake of ω-3 PUFAs.31 Oil
derived from cold-water fish is rich in ω-3 PUFAs, including
eicosapentaenoic acid (EPA) and docosapentaenoic acid (DHA).30
Studies evaluating the use of oral fish oil supplementation in psoriasis show conflicting results. Accurately assessing study quality is
paramount when trial results differ and wheremeta-analyses are not
possibleduetoheterogeneityofoutcomes.Double-blindRCTsareparticularly helpful in minimizing assessment bias. Among 9 doubleblind RCTs,12,30,33-39 oral supplementation with fish oil was shown to
be ineffective in reducing psoriasis severity in 7 of 9 trials; these data
are based on 449 patients enrolled in trials showing no benefit and
48 patients in trials showing benefit. The duration of supplementation in these trials ranged from 14 days to 7 months, and the daily dosage of EPA and DHA varied from 0.216 to 5.4 g and 0.132 to 3.6 g, respectively.
However, with regard to intravenous fish oil supplementation, 2 double-blind RCTs with a pooled population of 103
patients showed beneficial effects in reducing psoriasis
severity. 40,41 The duration of supplementation in these trials
ranged from 10 to 14 days, and the daily intravenous dosage of
both EPA and DHA varied from 2.1 to 4.2 g.

Level of
Evidencea Sourceb

2A

B

Gaál et al,45 2009;
Huckins et al,63
1990

“B” refers to limited-quality, patient-oriented evidence, which leads to a “weak
recommendation” (strength of recommendation 2A). Level of evidence “C”
refers to low-quality evidence, which leads to a “weak recommendation”
(strength of recommendation 2B).

Abbreviations: BMI, body mass index, calculated as weight in kilograms divided
by height in meters squared; check mark, positive recommendation, with
strength of recommendation indicated by number of check marks; ellipses,
neither positive nor negative recommendation; X, negative recommendation.
a

Strength of
Recommendation

b

Table exclusively includes sources from the highest level of evidence
supporting the corresponding strength of recommendation.

• Because evidence is limited regarding the effectiveness of intravenous fish oil supplementation on psoriasis in adults, a recommendation cannot be made at this time.
Vitamin D

Vitamin D can be given in different forms including cholecalciferol, alfacalcidol, and calcitriol.8 While topical vitamin D is well
established as an effective treatment option in psoriasis, the benefit of oral supplementation is less certain. Vitamin D deficiency is
common in patients with psoriasis,42 and lower levels of serum
vitamin D are associated with higher psoriasis severity.43 However, data are lacking regarding the effects of vitamin D supplementation on psoriasis severity in vitamin D–deficient patients.
Overall, high-quality evidence is lacking to support the use of vitamin D supplementation in psoriasis. Controlled studies show no benefit of vitamin D supplementation for improving skin disease severity over a period of 3 to 6 months.44,45 In comparison, some studies
show that improvement in skin disease severity can be seen after vitamin D supplementation over a period of 6 months or longer in patients with plaque or erythrodermic psoriasis.46-50 However, this is
based entirely on uncontrolled data. In addition, to date, there is no
clear evidence to support one form of vitamin D over another.
In individuals without a history of psoriasis, vitamin D intake
appears to have no impact on the development of psoriasis.51

Recommendation 3b: Vitamin D Supplementation
in Psoriasis
• We do not recommend oral vitamin D supplementation for prevention or treatment of psoriasis in adults with normal vitamin D
levels.

Selenium

Recommendation 3a: Fish Oil Supplementation
in Psoriasis
• We do not recommend oral fish oil supplementation for treatment of psoriasis in adults because oral fish oil was not effective
at the examined doses and durations.
946

Selenium is an essential nutrient that can affect the immune
system.52 Decreased selenium levels can be seen in patients with
psoriasis,52 and low selenium concentrations may be associated
with longer disease duration.53
Based on the available literature, selenium supplementation has
varying results in patients with different subtypes of psoriasis.52,54-56
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Specifically, in 1 small study (n = 28) evaluating inpatients with erythrodermic psoriasis, selenium supplementation with a combination
of 48 μg selenium aspartate, 50 mg coenzyme Q10 (ubiquinone acetate), and 50 mg vitamin E (α-tocopherol) daily seemed to be beneficial in conjunction with conventional therapy.54
However, selenomethionine supplementation provides no
benefit in patients with plaque psoriasis either as monotherapy or
in combination with phototherapy or topical therapy.52,55,56

Recommendation 3c: Selenium Supplementation
in Psoriasis
• We do not recommend selenium supplementation for treatment
of plaque psoriasis in adults.
• Because evidence is limited regarding the effectiveness of selenium supplementation on erythrodermic psoriasis in adults, a recommendation cannot be made at this time.
Vitamin B12

Based on the available literature, Vitamin B12 supplementation
appears to be ineffective as a therapeutic intervention in
psoriasis.57,58 When compared with patients treated with placebo, intramuscular high-dose vitamin B 12 was shown to be
ineffective.58

Recommendation 3d: Vitamin B12 Supplementation
in Psoriasis
• We do not recommend vitamin B12 supplementation for treatment of psoriasis in adults.

Review Clinical Review & Education

foods, nutrients, and dietary patterns to psoriasis severity varies,
which leads to the following recommendation.60,61 Additional
data from patient experiences help inform this topic5,27; however,
these observations are exploratory and subject to reporting bias.

Recommendation 4: Specific Foods, Nutrients,
or Dietary Patterns in Psoriasis
• Based on low-quality evidence, adults with psoriasis may consider a trial of a Mediterranean diet and consuming extra virgin olive oil as the main culinary lipid, at least 2 servings of vegetables
daily, at least 3 servings of fruits daily, legumes at least 3 times
weekly, fish or seafood at least 3 times weekly, tree nuts at least 3
times weekly, or sofrito sauce (tomatoes, onions, garlic, olive oil)
at least 2 times weekly.60
• Based on low-quality evidence, adults with psoriasis may consider a trial of consuming more ω-3 PUFAs, monounsaturated fatty
acids, fiber, or complex carbohydrates and consuming less total energy, saturated fatty acids, total PUFAs, ω-6 PUFAs, ω-6:ω-3 PUFA
ratio, or simple carbohydrates.61
• This weak recommendation (strength 2B) is based on level C
evidence.60,61

Question 5: Are Any of These Dietary Interventions Useful
for Patients With Psoriatic Arthritis?
Psoriatic arthritis affects approximately one-third of patients with
psoriasis.2 Determining the effects of dietary interventions on
psoriatic arthritis severity is important for overall disease
management.
Gluten-Free Diet

Micronutrients

Combination micronutrient supplementation may be beneficial in
plaque psoriasis. Specifically, compared with patients with psoriasis treated with low-dose methotrexate alone, those receiving
supplementation with a combination of vitamins and minerals (folic acid, magnesium, iron, zinc, copper, manganese, selenium, chromium, iodine, and vitamins A, D, E, K, C, B1, B2, B3, B6, and B12) for 3
months in conjunction with low-dose methotrexate had significantly greater improvement in psoriasis severity.11 However, this is
based on 1 small study (n = 34).

Recommendation 3e: Micronutrient Supplementation
in Psoriasis
• Because evidence is limited regarding the effectiveness of combination micronutrient supplementation on psoriasis in adults, a
recommendation cannot be made at this time.

All of the studies on gluten-free diet include patients with psoriatic
arthritis but do not assess arthritis disease severity or report outcomes separately in these patients.14-16 Therefore, it remains unknown whether gluten-free diet can help improve psoriatic arthritis severity.
Dietary Weight Reduction

Dietary weight reduction with a hypocaloric diet seems to be helpful in overweight and obese (BMI, ⱖ25) patients with psoriatic arthritis. Specifically, patients starting treatment with tumor necrosis factor blockers (etanercept, adalimumab, or infliximab) are
significantly more likely to achieve minimal arthritis disease activity and to experience weight loss after a 6-month hypocaloric diet
than after a regular diet.62

Dietary Supplements

Question 4: Are There Any Specific Foods, Nutrients,
or Dietary Patterns That Are Helpful or Harmful in Psoriasis?
A large proportion of patients with psoriasis report having tried a
special diet for their psoriasis,5 and a majority of patients believe
that diet regimen can improve psoriasis. 27 Although multiple
observational studies exist evaluating the dietary patterns of
patients with psoriasis,5,59-61 data demonstrating a relationship
with disease severity is limited. In general, the dietary patterns of
patients with psoriasis appear to be different from those of
patients without psoriasis (Table 1). The contribution of certain
jamadermatology.com

Whereas oral vitamin D supplementation seems to be ineffective in
improving skin disease severity, it may be beneficial in psoriatic arthritis. Specifically, uncontrolled studies show that 0.5 μg alfacalcidol or 0.5 to 2.0 μg calcitriol daily for 6 months leads to significant improvement in arthritis disease severity.45,63
In 1 small study (n = 30) evaluating inpatients with psoriatic arthritis, a combination of 48 μg selenium aspartate, 50 mg coenzyme Q10 (ubiquinone acetate), and 50 mg vitamin E (α-tocopherol)
daily seemed to be beneficial in conjunction with conventional
therapy.54
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Based on the literature, we determine fish oil supplementation to be ineffective in psoriatic arthritis. Compared with control
patients, patients supplementing with fish oil do not experience
signif icantly greater improvement in ar thritis disease
severity.12,33,34
There are no data on vitamin B12 or combination micronutrient supplementation in psoriatic arthritis.

Specific Foods, Nutrients, or Dietary Patterns

There are no data to support specific foods, nutrients, or dietary
patterns in psoriatic arthritis.

Recommendation 5: Dietary Interventions
in Psoriatic Arthritis
• In overweight or obese adults with psoriatic arthritis (BMI,
ⱖ25), we recommend dietary weight reduction with a hypocaloric diet as an adjunctive intervention to standard medical
therapies for psoriatic arthritis.
• In adults with psoriatic arthritis, we recommend a trial of oral
vitamin D supplementation (0.5 μg alfacalcidol or 0.5-2.0 μg calcitriol daily) as an adjunctive intervention to standard medical
therapies for psoriatic arthritis.
• Because evidence is limited regarding the effectiveness of selenium supplementation on psoriatic arthritis in adults, a recommendation cannot be made at this time.
• We do not recommend fish oil supplementation for treatment of
psoriatic arthritis in adults.
• These weak recommendations (strength 2A) are based on
level B evidence; limitations include a lack of randomization,45
uncontrolled data,45,63 and study-related bias.45

ARTICLE INFORMATION
Accepted for Publication: April 10, 2018.
Published Online: June 20, 2018.
doi:10.1001/jamadermatol.2018.1412
Author Affiliations: Keck School of Medicine,
University of Southern California, Los Angeles
(Ford, Armstrong); National Psoriasis Foundation,
Portland, Oregon (M. Siegel); Psoriasis Treatment
Center of Central New Jersey, East Windsor (Bagel);
Department of Dermatology, University of
California San Francisco (Cordoro, Koo, Liao);
Department of Pediatrics, University of California
San Francisco (Cordoro); Department of
Dermatology, Zucker School of Medicine at Hofstra
/Northwell, Hempstead, New York (Garg); New
York Medical College at Metropolitan Hospital, New
York (Gottlieb); Hudson Dermatology, Somers, New
York (Gottlieb); Department of Dermatology,
George Washington University School of Medicine,
Washington, DC (Green, Prussick); Department of
Dermatology, University of Michigan, Ann Arbor
(Gudjonsson); Icahn School of Medicine at Mount
Sinai, New York, New York (Lebwohl);
Northwestern University Feinberg School of
Medicine, Chicago, Illinois (Mandelin); Hospital for
Special Surgery, Weill Medical College of Cornell
University, New York-Presbyterian Hospital,
New York (Markenson, Schwartzman); National
Heart, Lung, and Blood Institute, National Institutes
of Health, Bethesda, Maryland (Mehta); Brigham
948

Discussion
In this article, we made evidence-based recommendations on the
impact of diet in adults with psoriatic diseases. We highlight 3 concepts important for interpreting these recommendations. First, it is
universally important to continue regular medical treatment for psoriatic diseases. We do not recommend relying on dietary interventions as the sole source of treatment. Second, dietary interventions can be associated with adverse effects and contraindications.
Third, these dietary recommendations may have impact beyond patients’ skin and joints and may affect one’s general health.5,64,65
The findings of this systematic review are dependent on the
strength of the primary literature. Some studies are not randomized, blinded, or controlled, which may introduce bias. There is
heterogeneity among studies with regard to populations studied,
interventions used, and outcomes measured.

Conclusions
Dietary interventions, when implemented, should be used in conjunction with standard medical therapies for psoriatic diseases. We
strongly recommend dietary weight reduction with a hypocaloric diet
in overweight and obese patients with psoriasis. We weakly recommend a gluten-free diet only in patients who test positive for serologic markers of gluten sensitivity. Based on low-quality data, select foods, nutrients, and dietary patterns may affect psoriasis. For
patients with psoriatic arthritis, we weakly recommend vitamin D
supplementation and dietary weight reduction with a hypocaloric
diet in overweight and obese patients.
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